ES2058490T3 - Metodo de reducir respuestas de inmunoglobulina e. - Google Patents

Metodo de reducir respuestas de inmunoglobulina e.

Info

Publication number
ES2058490T3
ES2058490T3 ES89300872T ES89300872T ES2058490T3 ES 2058490 T3 ES2058490 T3 ES 2058490T3 ES 89300872 T ES89300872 T ES 89300872T ES 89300872 T ES89300872 T ES 89300872T ES 2058490 T3 ES2058490 T3 ES 2058490T3
Authority
ES
Spain
Prior art keywords
responses
antagonist
reducing immunoglobulin
human interleukin
immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89300872T
Other languages
English (en)
Inventor
Robert L Coffman
Vries Jan Egbert De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Schering Biotech Corp
Original Assignee
Schering Biotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22538655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2058490(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Biotech Corp filed Critical Schering Biotech Corp
Application granted granted Critical
Publication of ES2058490T3 publication Critical patent/ES2058490T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE PRESENTA UN METODO PARA LA REDUCCION DE LAS RESPUESTAS A LA INMUNOGLOBULINA E ASOCIADAS CON CIERTOS DESORDENES INMUNOLOGICOS. EL METODO INCLUYE LA ADMINISTRACION DE UNA CANTIDAD EFECTIVA DE UN ANTAGONISTA DE LA INTERLEUQUINA - 4 HUMANA. EL ANTAGONISTA ES PREFERIBLEMENTE UN ANTICUERPO MONOCLONAL DE BLOQUEO, ESPECIFICO PARA LA INTERLEUQUINA - 4 DEL HOMBRE, O UN FRAGMENTO O COMPOSICION AGLUTINANTE DERIVADA DE ELLA.
ES89300872T 1988-02-02 1989-01-30 Metodo de reducir respuestas de inmunoglobulina e. Expired - Lifetime ES2058490T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15141388A 1988-02-02 1988-02-02

Publications (1)

Publication Number Publication Date
ES2058490T3 true ES2058490T3 (es) 1994-11-01

Family

ID=22538655

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89300872T Expired - Lifetime ES2058490T3 (es) 1988-02-02 1989-01-30 Metodo de reducir respuestas de inmunoglobulina e.

Country Status (20)

Country Link
US (1) US5676940A (es)
EP (2) EP0327283B1 (es)
JP (1) JPH03500050A (es)
KR (1) KR900700132A (es)
AT (1) ATE93144T1 (es)
AU (1) AU629536B2 (es)
CA (1) CA1341477C (es)
DE (1) DE68908431T2 (es)
DK (1) DK183590A (es)
ES (1) ES2058490T3 (es)
FI (1) FI903827A0 (es)
HK (1) HK35196A (es)
HU (1) HU211059B (es)
IE (1) IE63097B1 (es)
IL (1) IL89124A (es)
MY (1) MY107079A (es)
NZ (1) NZ227812A (es)
PT (1) PT89573B (es)
WO (1) WO1989006975A1 (es)
ZA (1) ZA89766B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
DE69006221T2 (de) * 1989-12-04 1994-05-05 Fletcher Starnes H Verfahren zur behandlung von septischem schock.
IL96714A0 (en) * 1989-12-20 1991-09-16 Schering Corp Antibody antagonists of human interleukin-4
US5252677A (en) * 1990-11-20 1993-10-12 Mitsubishi Petrochemical Company Limited Functionalized olefin polymers
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5928904A (en) * 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US20020193575A1 (en) * 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US6919366B2 (en) 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6911462B2 (en) 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6759425B2 (en) 1999-10-21 2004-07-06 Avanir Pharmaceuticals Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
DE16192152T1 (de) 2000-05-26 2020-08-06 Immunex Corporation Verwendung von interleukin-4 rezeptor (il-4r) antikörpern und zusammensetzungen davon
ATE369853T1 (de) 2001-03-12 2007-09-15 Avanir Pharmaceuticals Benzimidazolderivate zur ige-modulierung und zellproliferationshemmung
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
AR050044A1 (es) 2004-08-03 2006-09-20 Novartis Ag Anticuerpo especifico de il-4
US10196616B2 (en) 2017-02-15 2019-02-05 The United States Of America, As Represented By The Secretary Of Agriculture Altered avian virus for in-ovo inoculation and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
PT83761B (pt) * 1985-11-19 1989-06-30 Schering Biotech Corp Metodo para a producao de interleuquina-4 de mamifero
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
EP0255547A1 (en) * 1986-07-29 1988-02-10 Kishimoto, Tadamitsu, Prof. Monoclonal antibodies specific to surface receptor for IgE and hybrid cell lines producing these antibodies and use thereof
EP0407392B2 (en) * 1987-12-31 1998-10-28 Tanox Biosystems, Inc. UNIQUE ANTIGENIC EPITOPES ON IgE-BEARING B LYMPHOCYTES

Also Published As

Publication number Publication date
DK183590A (da) 1990-09-27
IE63097B1 (en) 1995-03-22
US5676940A (en) 1997-10-14
DK183590D0 (da) 1990-08-01
HU891044D0 (en) 1990-11-28
PT89573A (pt) 1989-10-04
EP0397764A1 (en) 1990-11-22
DE68908431D1 (de) 1993-09-23
MY107079A (en) 1995-09-30
NZ227812A (en) 1991-09-25
FI903827A0 (fi) 1990-08-01
IL89124A0 (en) 1989-08-15
EP0327283A1 (en) 1989-08-09
JPH03500050A (ja) 1991-01-10
PT89573B (pt) 1994-01-31
IL89124A (en) 1994-10-21
DE68908431T2 (de) 1993-12-23
AU3038389A (en) 1989-08-25
EP0327283B1 (en) 1993-08-18
KR900700132A (ko) 1990-08-11
ATE93144T1 (de) 1993-09-15
CA1341477C (en) 2005-03-29
ZA89766B (en) 1989-09-27
HU211059B (en) 1995-10-30
HK35196A (en) 1996-03-08
AU629536B2 (en) 1992-10-08
WO1989006975A1 (en) 1989-08-10
IE890302L (en) 1989-08-02
HUT54214A (en) 1991-01-28

Similar Documents

Publication Publication Date Title
ES2058490T3 (es) Metodo de reducir respuestas de inmunoglobulina e.
NL300387I1 (nl) Antilichaam tegen menselijke interleukine-6-receptor
EE03285B1 (et) Immuunsust stimuleerivad monoklonaalsed antikehad
ES2062032T3 (es) Antagonista de interleuquina-5 para prevenir o reducir la eosinofilia.
ES2062762T3 (es) Metodo para tratar el choque septico.
DK134487D0 (da) Monoklonalt antistof med affinitet for humant interleukin-2
FI924278A0 (fi) Bcrf1 antagonister foer skoetsel av epstein-barr-virusinfektioner.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 327283

Country of ref document: ES